Biogen and Sobi Announce EMA Validates Alprolix (rFIXFc) Marketing Authorization Application
Biogen and Swedish Orphan Biovitrum AB (publ) (Sobi) have announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) of Alprolix (rFIXFc), a recombinant factor IX Fc fusion protein product candidate for the treatment of hemophilia B. This validation signifies the initiation of the EMA’s review process.
The MAA includes results from two global, Phase III clinical trials examining the efficacy, safety and pharmacokinetics of Alprolix for hemophilia B: the pivotal B-LONG study for previously treated adults and adolescents, and Kids B-LONG study for previously treated children under age 12.
ALPROLIX is a recombinant, clotting factor IX therapy and is currently approved for the treatment of hemophilia B in the US, Canada, Japan and Australia. It is the only approved hemophilia B therapy to demonstrate prolonged clotting factor circulation in the body.
“The acceptance of this MAA is an important milestone in our goal to bring this innovative therapy to the European hemophilia community,” said Douglas E. Williams, executive vice president of R&D at Biogen. “We look forward to working with European regulators to help people with hemophilia B in Europe realize the benefits that treatment with Alprolix may offer.”
Biogen and Sobi are collaborators in the development and commercialization of Alprolix for hemophilia B. Sobi has an opt-in right to assume final development and commercialization of Alprolix for the Sobi territories (essentially, Europe, North Africa, Russia and certain Middle Eastern markets). Biogen leads development for Alprolix, has manufacturing rights, and has commercialization rights in North America and all other regions in the world excluding the Sobi territories.
“Our collaboration with Biogen remains focused on the goal of transforming the care of people living with hemophilia,” said Birgitte Volck, senior vice president of Development and chief medical officer of Sobi. “The validation of the Alprlix MAA marks a critical regulatory milestone in our continued, collaborative global efforts.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance